← Back to Screener
Nektar Therapeutics (NKTR)
Price$100.35
Favorite Metrics
Price vs S&P 500 (26W)47.42%
Price vs S&P 500 (4W)8.01%
Market Capitalization$2.87B
All Metrics
Book Value / Share (Quarterly)$4.41
P/TBV (Annual)2.92x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-15.67%
Cash Flow / Share (Quarterly)$-10.27
Price vs S&P 500 (YTD)96.57%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-285.59%
EPS (TTM)$-9.81
10-Day Avg Trading Volume0.57M
EPS Excl Extra (TTM)$-9.81
Revenue Growth (5Y)-18.43%
EPS (Annual)$-9.73
ROI (Annual)-107.25%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-327.61%
Cash / Share (Quarterly)$12.06
Revenue Growth QoQ (YoY)-25.25%
ROA (Last FY)-58.51%
Revenue Growth TTM (YoY)-43.89%
EBITD / Share (TTM)$-8.23
ROE (5Y Avg)-153.36%
Operating Margin (TTM)-253.66%
Cash Flow / Share (Annual)$-10.27
P/B Ratio32.00x
P/B Ratio (Quarterly)9.57x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)52.91x
Net Interest Coverage (TTM)-8.87x
ROA (TTM)-60.35%
EV / EBITDA (TTM)4.39x
EPS Incl Extra (Annual)$-9.73
Current Ratio (Annual)4.97x
Quick Ratio (Quarterly)4.62x
3-Month Avg Trading Volume1.04M
52-Week Price Return827.43%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.15
P/S Ratio (Annual)52.04x
Asset Turnover (Annual)0.20x
52-Week High$86.95
Operating Margin (5Y Avg)-299.88%
EPS Excl Extra (Annual)$-9.73
CapEx CAGR (5Y)-34.68%
Tangible BV CAGR (5Y)2.06%
26-Week Price Return56.16%
Quick Ratio (Annual)4.62x
13-Week Price Return135.13%
Total Debt / Equity (Annual)0.70x
Current Ratio (Quarterly)4.97x
Enterprise Value$2,922.288
Revenue / Share Growth (5Y)30.77%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)-5.92%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)3.81x
Pretax Margin (Annual)-281.52%
Cash / Share (Annual)$12.06
3-Month Return Std Dev118.77%
Gross Margin (5Y Avg)76.67%
Net Income / Employee (TTM)$-3
ROE (Last FY)-182.65%
Net Interest Coverage (Annual)-8.87x
EPS Basic Excl Extra (Annual)$-9.73
P/FCF (TTM)2.74x
Receivables Turnover (TTM)163.36x
Total Debt / Equity (Quarterly)0.70x
EPS Incl Extra (TTM)$-9.81
Receivables Turnover (Annual)163.36x
ROI (TTM)-84.30%
P/S Ratio (TTM)52.04x
Pretax Margin (5Y Avg)-323.80%
Revenue / Share (Annual)$3.27
Tangible BV / Share (Annual)$2.29
Price vs S&P 500 (52W)792.34%
Year-to-Date Return100.71%
5-Day Price Return5.48%
EPS Normalized (Annual)$-9.73
ROA (5Y Avg)-53.15%
Net Profit Margin (Annual)-297.07%
Month-to-Date Return17.94%
Cash Flow / Share (TTM)$-1.50
EBITD / Share (Annual)$-8.22
Operating Margin (Annual)-253.66%
LT Debt / Equity (Annual)0.70x
ROI (5Y Avg)-95.22%
LT Debt / Equity (Quarterly)0.70x
EPS Basic Excl Extra (TTM)$-9.81
P/TBV (Quarterly)3.11x
P/B Ratio (Annual)9.57x
Inventory Turnover (TTM)3.81x
Pretax Margin (TTM)-281.52%
Book Value / Share (Annual)$4.41
Price vs S&P 500 (13W)132.27%
Beta1.22x
P/FCF (Annual)4.08x
Revenue / Share (TTM)$2.72
ROE (TTM)-184.69%
52-Week Low$7.99
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.31
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NKTRNektar Therapeutics | 52.04x | -43.89% | 100.00% | — | $100.35 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Nektar Therapeutics is a biopharmaceutical company developing immunotherapy medicines in clinical development. Its pipeline includes REZPEG (NKTR-358), NKTR-422, NKTR-0165, and NKTR-255, among other candidates. The company focuses on discovering and developing novel therapeutics to address unmet medical needs in immunology.